Clinical Trial Update: Virological Response Study of the HCV Vaccine IC41 [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the HCV vaccine IC41 in chronic hepatitis C has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• IC41

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED